search
Back to results

O-ARM Stereotactic Imaging in Deep Brain Stimulation for Parkinson's Disease (STEREOBLOC)

Primary Purpose

Parkinson Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Stereotactic imaging
Sponsored by
University Hospital, Toulouse
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Parkinson Disease focused on measuring Stereotactic imaging, Deep Brain Stimulation

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with a diagnosis of idiopathic Parkinson's disease at the stage of motor fluctuations despite optimal medical treatment Indication for Deep Brain Stimulation (DBS) of the subthalamic nucleus approved by the local multidisciplinary deep brain stimulation committee after an operability assessment (see Appendix) Informed and signed patient consent Affiliation to a social security scheme Exclusion Criteria: Significant cognitive decline assessed in a dedicated multidisciplinary consultation Contraindication to Magnetic Resonance Imaging (MRI) Presence of pathologies contraindicating deep brain stimulation No contraceptive treatment for women of childbearing age Pregnant or breastfeeding woman Anticoagulant or antiaggregant treatment that cannot be stopped Persons under legal protection (persons deprived of liberty or incapable of giving consent or under guardianship or tutelage...) Patient with severe psychiatric disorders

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    O-Arm stereotactic imaging

    Standard stereotactic imaging

    Arm Description

    Imaging is performing directly in the operating room.

    Imaging is performing in Radiology department.

    Outcomes

    Primary Outcome Measures

    The absolute accuracy of Deep Brain Stimulation electrode implantation
    The radial distance between the theoretical target and the electrode in the plane of the target regardless of the chosen trajectory (central, anterior, lateral). This distance corresponds to the minimum error between the target and the electrode. This measurement is made from the postoperative brain scan.

    Secondary Outcome Measures

    The anatomical accuracy of Deep Brain Stimulation electrode implantation
    Automatic calculation of the vector distance between the middle of pad 1 on the electrode and the theoretical target by logicial.
    Central and alternate position of the electrodes rate
    Comparison of the anatomical location of the electrode compared to the anatomical target (subthalamic nucleus) after matching preoperative Magnetic Resonance Imaging (MRI) images
    Surgical Times
    Time from the end of the stereotactic frame to the surgical incision and time from the entry into room to the exit from room after generator implantation.
    Clinical effectiveness
    Comparison of The Unified Parkinson's Disease Rating Scale (UPDRS) II, III and IV scores between baseline and 6 months and then at 6 months between the 2 groups. The UPDRS scale is composed of 47 items grouped into three parts : II, III and IV. Responses scale ranging from 0 (normal/no symptoms) to 4 (severe).
    Daily dose of Levodopa decrease
    The change in Levodopa Equivalent Daily Dose (LEDD) before surgery and at 6 months compared between the 2 groups. This LEDD corresponds to the amount of antiparkinsonian treatments prescribed to the patient
    Adverse effect rate
    Clinical reporting of patient events/adverse reactions
    Correlation between absolute accuracy and clinical effectiveness
    Correlation between radial accuracy and UPDRS score for both groups

    Full Information

    First Posted
    June 8, 2023
    Last Updated
    June 19, 2023
    Sponsor
    University Hospital, Toulouse
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05910008
    Brief Title
    O-ARM Stereotactic Imaging in Deep Brain Stimulation for Parkinson's Disease
    Acronym
    STEREOBLOC
    Official Title
    Evaluation of Intraoperative O-ARM Stereotactic Imaging Versus Conventional Pre-operative Stereotactic Imaging in Deep Brain Stimulation for Parkinson's Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    July 15, 2023 (Anticipated)
    Primary Completion Date
    December 15, 2024 (Anticipated)
    Study Completion Date
    June 15, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Toulouse

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    During deep brain stimulation procedures in Parkinson's disease (PD), the most important prognostic element is the positioning of the surgical electrode in the subthalamic nucleus which is the anatomical target. The main objective of this project is therefore to compare 2 techniques thanks to a prospective comparative randomised open-label study: the use of O-ARM to acquire stereotactic imaging directly in the operating room and the standard technique requiring stereotactic imaging to be performed in the radiology department.
    Detailed Description
    Prior to electrode implantation we perform stereotactic imaging which requires the fixation of a stereotactic frame on the patient's head before imaging (Magnetic Resonance Imaging MRI / Computed Tomography CT). Currently, it is necessary to transfer the patient to the imaging department outside of the operating room after the stereotactic frame has been placed, for imaging (either MRI or CT) and then to return to the operating room to begin the electrode implantation procedure. Since 2016, the new generation O-Arm 2 allows the acquisition of stereotactic imaging with the stereotactic frame in place by increasing the field of view (40 cm versus 20 cm previously) directly in the operating room. As a result, the transfer step to the MRI and CT scanner preoperatively may no longer be necessary, and the procedure can be started more quickly with greater comfort and safety for the patient and the anaesthesia team. Several teams around the world have begun to use framed O-Arm as the gold standard for stereotactic imaging. However, no randomised controlled study has been performed to date comparing O-Arm stereotactic imaging with pre-operative CT and/or MRI reference imaging.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Parkinson Disease
    Keywords
    Stereotactic imaging, Deep Brain Stimulation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    24 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    O-Arm stereotactic imaging
    Arm Type
    Experimental
    Arm Description
    Imaging is performing directly in the operating room.
    Arm Title
    Standard stereotactic imaging
    Arm Type
    Active Comparator
    Arm Description
    Imaging is performing in Radiology department.
    Intervention Type
    Procedure
    Intervention Name(s)
    Stereotactic imaging
    Intervention Description
    Prior to electrode implantation , stereotactic imaging (Magnetic Resonance Imaging )
    Primary Outcome Measure Information:
    Title
    The absolute accuracy of Deep Brain Stimulation electrode implantation
    Description
    The radial distance between the theoretical target and the electrode in the plane of the target regardless of the chosen trajectory (central, anterior, lateral). This distance corresponds to the minimum error between the target and the electrode. This measurement is made from the postoperative brain scan.
    Time Frame
    48 hours
    Secondary Outcome Measure Information:
    Title
    The anatomical accuracy of Deep Brain Stimulation electrode implantation
    Description
    Automatic calculation of the vector distance between the middle of pad 1 on the electrode and the theoretical target by logicial.
    Time Frame
    48 hours
    Title
    Central and alternate position of the electrodes rate
    Description
    Comparison of the anatomical location of the electrode compared to the anatomical target (subthalamic nucleus) after matching preoperative Magnetic Resonance Imaging (MRI) images
    Time Frame
    1 day
    Title
    Surgical Times
    Description
    Time from the end of the stereotactic frame to the surgical incision and time from the entry into room to the exit from room after generator implantation.
    Time Frame
    1 day
    Title
    Clinical effectiveness
    Description
    Comparison of The Unified Parkinson's Disease Rating Scale (UPDRS) II, III and IV scores between baseline and 6 months and then at 6 months between the 2 groups. The UPDRS scale is composed of 47 items grouped into three parts : II, III and IV. Responses scale ranging from 0 (normal/no symptoms) to 4 (severe).
    Time Frame
    6 months
    Title
    Daily dose of Levodopa decrease
    Description
    The change in Levodopa Equivalent Daily Dose (LEDD) before surgery and at 6 months compared between the 2 groups. This LEDD corresponds to the amount of antiparkinsonian treatments prescribed to the patient
    Time Frame
    6 months
    Title
    Adverse effect rate
    Description
    Clinical reporting of patient events/adverse reactions
    Time Frame
    6 months
    Title
    Correlation between absolute accuracy and clinical effectiveness
    Description
    Correlation between radial accuracy and UPDRS score for both groups
    Time Frame
    6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with a diagnosis of idiopathic Parkinson's disease at the stage of motor fluctuations despite optimal medical treatment Indication for Deep Brain Stimulation (DBS) of the subthalamic nucleus approved by the local multidisciplinary deep brain stimulation committee after an operability assessment (see Appendix) Informed and signed patient consent Affiliation to a social security scheme Exclusion Criteria: Significant cognitive decline assessed in a dedicated multidisciplinary consultation Contraindication to Magnetic Resonance Imaging (MRI) Presence of pathologies contraindicating deep brain stimulation No contraceptive treatment for women of childbearing age Pregnant or breastfeeding woman Anticoagulant or antiaggregant treatment that cannot be stopped Persons under legal protection (persons deprived of liberty or incapable of giving consent or under guardianship or tutelage...) Patient with severe psychiatric disorders
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Amaury De Barros, MD
    Phone
    561779027
    Ext
    +33
    Email
    debarros.a@chu-toulouse.fr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Amaury De Barros, MD
    Organizational Affiliation
    University Hospital, Toulouse
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    O-ARM Stereotactic Imaging in Deep Brain Stimulation for Parkinson's Disease

    We'll reach out to this number within 24 hrs